19 February 2016 - Deborah Wilkes
Archived
An advisory committee to the US Food and Drug Administration (FDA) is set to consider Galderma's application to switch adapalene – the active ingredient of its acne medicine Differin – from prescription to OTC status.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.